Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
RESEARCH TOOLSreports
ACRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.17
Previous CloseN/A
Volume227.82K
Average Volume (3M)836.67K
Market Cap
$249.35M
Enterprise Value-$42.92M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Feb 20, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding107,018,740
10 Day Avg. Volume588,352
30 Day Avg. Volume836,668
Standard Deviation0.41
R-Squared0.00444
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.15
Price to Cash Flow (P/CF)1.90
P/FCF Ratio1.90
Enterprise Value/Market Cap-0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.26
Enterprise Value/Ebitda0.70
Forecast
1Y Price Target
$11.25Price Target Upside387.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Aclaris Therapeutics News
PremiumPre-Earnings
Is ACRS a Buy, Before Earnings?
PremiumCompany Announcements
Aclaris Therapeutics Highlights Drug Progress and Financial Strength
---
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyBSI-045B showed promising results in a Phase 2a study for atopic dermatitis, with high efficacy rates compared to currently approved therapies.
Financial BackingAn $80 million private placement was announced to support the company's newly bolstered pipeline and operational efforts, showing strong investor interest and financial backing.
Licensing And PipelineTransformative licensing transaction revitalizes pipeline with renewed focus on biologic candidates—upgrading to Buy.
Bears Say
Clinical RisksThere are clinical, regulatory, and commercial risks associated with Aclaris Therapeutics' pipeline products.
Market CompetitionLegacy pipeline programs may generate additional value, but face competition from existing market players.
Regulatory RisksOngoing progress in the pipeline includes plans for a P2b trial for BSI-045B and an IND submission for BSI-052, indicating potential regulatory hurdles.
---
Ownership Overview
29.40% Insiders
4.88% Mutual Funds
0.42% Other Institutional Investors
59.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $0.95 and its highest was $5.17 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $249.35M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is today.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.006 by -$0.104.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 107,018,740 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.006. Following the earnings report the stock price went up 1.802%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Among the largest hedge funds holding Aclaris Therapeutics’s share is Aisling Capital Management LP. It holds Aclaris Therapeutics’s shares valued at 0.
---
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (387.01% Upside)
$11.25 (387.01% Upside)
Hedge Fund Trend
Decreased
By 434.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 11.0%
Last 30 Days ▼ 11.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
93.27%
12-Months-Change
Fundamentals
Return on Equity
-25.83%
Trailing 12-Months
Asset Growth
-16.47%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
ACRS Stock 12 Month Forecast
Average Price Target
$11.25
▲(387.01% Upside)
Technical Analysis
Best Analysts Covering ACRS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-31.26%
reiterated a buy rating 2 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -31.26% per trade.
---